Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

Tyrosine Kinase ◽

Cardiovascular Risk Factors ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Therapy Assessment ◽

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia

American Journal of Hematology ◽

10.1002/ajh.24495 ◽

2016 ◽

Vol 91 (11) ◽

pp. E480-E481 ◽

Cited By ~ 5

Author(s):

Simone Claudiani ◽

Jane F. Apperley ◽

Simona Deplano ◽

Jamshid Khorashad ◽

Letizia Foroni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Cognitive Dysfunction ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

GRP-011 Adherence to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2013-000276.011 ◽

2013 ◽

Vol 20 (Suppl 1) ◽

pp. A4.3-A5

Author(s):

V González Rosa ◽

MM Viña Romero ◽

F Gutiérrez Nicolás ◽

R Gavira Moreno ◽

MT Moreno Carvajal ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-015-2101-4 ◽

2016 ◽

Vol 142 (5) ◽

pp. 1041-1050 ◽

Cited By ~ 13

Author(s):

Mohamed El Missiry ◽

Shady Adnan Awad ◽

Hanna L Rajala ◽

Ahmed Al-Samadi ◽

Marja Ekblom ◽

...

Keyword(s):

Bone Marrow ◽

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Therapy Response ◽

Inhibitor Therapy ◽

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Leukemia Research ◽

10.1016/j.leukres.2020.106310 ◽

2020 ◽

Vol 90 ◽

pp. 106310 ◽

Cited By ~ 1

Author(s):

Stina Söderlund ◽

Inger Persson ◽

Mette Ilander ◽

Joëlle Guilhot ◽

Henrik Hjorth-Hansen ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy ◽

Plasma Proteomics

Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects

10.1111/bjh.12648 ◽

2013 ◽

Vol 164 (4) ◽

pp. 608-610 ◽

Cited By ~ 3

Author(s):

Pratap Neelakantan ◽

Katayoun Rezvani ◽

Philippa May ◽

Gareth Gerrard ◽

Bua Marco ◽

...

Keyword(s):

Side Effects ◽

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Cytogenetic Response ◽

Inhibitor Therapy ◽

Excellent Outcome ◽

The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial

10.1111/bjh.15629 ◽

2018 ◽

Vol 185 (4) ◽

pp. 791-793 ◽

Cited By ~ 4

Author(s):

Gemma M. Austin ◽

Katy Knight ◽

Joanne Bell ◽

Anthony Carter ◽

Earnest Heartin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Lymphocyte Subsets ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

BCR-ABL1transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib

10.1111/bjh.12187 ◽

2012 ◽

Vol 160 (5) ◽

pp. 630-639 ◽

Cited By ~ 16

Author(s):

Dennis D. Kim ◽

Honggi Lee ◽

Suzanne Kamel-Reid ◽

Jeffrey H. Lipton

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Second Generation ◽

Kinase Inhibitor ◽

Chronic Phase ◽

Long Term Outcomes ◽

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30192-x ◽

2018 ◽

Vol 19 (6) ◽

pp. 747-757 ◽

Cited By ~ 170

Author(s):

Susanne Saussele ◽

Johan Richter ◽

Joelle Guilhot ◽

Franz X Gruber ◽

Henrik Hjorth-Hansen ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Interim Analysis ◽

Kinase Inhibitor ◽

Randomised Trial ◽

Inhibitor Therapy ◽

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(19)30094-8 ◽

2019 ◽

Vol 6 (7) ◽

pp. e375-e383 ◽

Cited By ~ 40

Author(s):

Richard E Clark ◽

Fotios Polydoros ◽

Jane F Apperley ◽

Dragana Milojkovic ◽

Katherine Rothwell ◽

...

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Treatment Discontinuation ◽

Phase 2 ◽

Phase 2 Trial ◽

Tyrosine Kinase Inhibitor Therapy ◽

Complete Treatment

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy

10.1111/bjh.14973 ◽

2017 ◽

Vol 180 (1) ◽

pp. 24-32 ◽

Cited By ~ 22

Author(s):

Delphine Rea ◽

François-Xavier Mahon

Keyword(s):

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽